Problems of creating predictive models of the COVID19 coronavirus pandemic

Cover Page


Relevance. The article is devoted to creating prognostic models based on epidemiological and immunological data. Objective: to study the comparative dynamic epidemiological and immunological characteristics of patients with COVID-19. Materials and methods. Methodological approaches to the use of system analysis of epidemiological and immunological characteristics of patients with COVID-19 using multivariate analysis are described. The used technologies of computer-aided analysis systems, algorithms for recognizing, measuring and identifying the condition of patients, and methods of statistical data processing made it possible to create a universal information predictive model for calculating the dynamics of infectious diseases prone to generalization (pandemics), as well as to understand in which groups these new infectious diseases are most dangerous. Results and discussion. Using the methods of system analysis, the epidemiological and immunological aspects of predictive models of the coronavirus pandemic were evaluated using the most objective international data, which increased the information content of the analysis. Conclusions . Creating predictive epidemiological and immunological models of the pandemic is an urgent and promising task to combat the medical and social consequences of the spread of coronavirus infection in Russia.

About the authors

E. A. Levkova

Peoples’ Friendship University of Russia (RUDN University)

Author for correspondence.
Moscow, Russian Federation

R. I. Sepiashvili

Peoples’ Friendship University of Russia (RUDN University)

Moscow, Russian Federation

S. Z. Savin

Pacific National University

Khabarovsk, Russian Federation


  1. The world health organization. Clinical guidelines for the management of patients with severe acute respiratory infections with suspected mers-Cov infection. Temporary recommendations. [Electronic resource]. Publication date: July 2015. URL: disease/coronavirus_infections/case-management-ipc/ru. (in Russ).
  2. Bouadma L, Lescure FX, Lucet JC, et al. Severe SARSCoV-2 infections: practical considerations and management strategy for intensivists. Intensive Care Med. 2020;46:579—582. doi: 10.1007/ s00134-020-05967-x
  3. Chaolin H, Yeming W, Xingwang L, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395:497—506.
  4. Espinoza RT, Kellner CH, McCall WV. ECT during COVID-19: An Essential Medical Procedure – Maintaining Service Viability and Accessibility. J ECT. 2020;4:9.
  5. Boldyreva MN. SARS-CoV-2 virus and other epidemic coronaviruses: pathogenetic and genetic factors of infection development. Immunology. 2020;41(3):197—205. (in Russ).
  6. Zhuikov BL. What determines the spread of coronavirus and lethality. Troicky version. 2020;7:4. [Electronic resource] https:// (in Russ).
  7. Mayansky NA. Immunity to COVID-19 and issues of screening studies of antibodies to SARS-Cov-2. Bulletin of RSMU. 2020;3:27—30. (in Russ).
  8. Cross-country analysis. WHO Coronavirus Disease (COVID-19). Available from: https://analysis.covid19healthsystem. org/index.php/ru/latest-posts-ru (in Russ).
  9. MMWR Morb. Mortal Wkly Rep. 2020;69:1049—1057. doi: icon.
  10. World Health Organisation. Coronavirus Disease (COVID-19) Dashboard. Available from:
  11. Anderson R. Infectious diseases of the person. Dynamics and control. Moscow: Mir. 2004:784. (in Russ).
  12. Lobzin YuV, Belozerov ES, Belyaeva TV, Volzhanin VM. Human viral diseases. SPb.: SpetsLit. 2015. 400 p. (in Russ).
  13. L’vov DK, Alkhovsky SV, Kolobukhina LV, Burtseva EI. Etiology of the COVID-19 epidemic outbreak in Wuhan (Hubei province, people’s Republic of China) associated with the 2019-nCoV virus (Nidovirales, Coronaviridae, Coronavirinae, Betacoronavirus, subgenus Sarbecovirus): lessons from the SARS-CoV epidemic. Questions of Virology. 2020;65(1):6—16. (in Russ).
  14. Levkova EA, Savin SZ, Gulieva KA. RNA-containing viruses: clinical and diagnostic features and principles of treatment. Therapist. 2020;4(157):65—73. (in Russ).
  15. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514—523.
  16. Lipsitch M, Swerdlow DL, Finelli L. Defining the epidemiology of Covid-19 – studies needed. N. Engl. J. Med. 2020;382:1194—6.
  17. Zhmerenetsky KV, Sazonova EN, Voronina NV, Tomilka GS, Senkevich OA, Gorokhovsky VS, et al. COVID-19: Only scientific facts. Far Eastern Medical Journal. 2020;1:5—22. (in Russ).
  18. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus, pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7.
  19. Fedson DS, Opal SM, Rordam OM. Hiding in plain sight: an approach to treating patients with severe COVID-19 infection. mBio. 2020;11(2):e00398-20. doi: 10.1128/mBio.00398-20.
  20. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19). J. Autoimmun. 2020;109:102433.
  21. Swerdlow D L, Finelli L, Lipsitch M. Epidemiology of Covid-19. NEJM. 2020;3:27.
  22. Grasselli G, Pesenti A, Cecconi M. Critical care utilization for the COVID-19. Outbreak in Lombardy, Italy: early experience and forecast during an emergency response. JAMA. 2020: doi10.1001/ jama.2020.4031.
  23. Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382:929—936. doi: 10.1056/NEJMoa200119.
  24. Hui DS, Azhar EI, Madani TA. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - the latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020;91:264—266.
  25. Lakdawala SS, Menachery VD. The search for a COVID-19 animal model. Science. 29 May 2020:368(6494):942—943. doi: 10.1126/science.abc6141
  26. Summary of the progress made by the WHO COVID-19 modeling ad hoc expert working group. World Health Organisation. COVID-19 Animal Models. R&D Blueprint. 2020:16.
  27. World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance [Internet]. Geneva: World Health Organization; 2020 Mar/ [cited 2020 Jul/ 7]. Available from: docs/default-source/coronaviruse/clinical-management-of-novel-cov. pdf?sfvrsn=bc7da517_2.
  28. Federal service for supervision of consumer rights protection and human welfare. About a new coronavirus infection. 2020. Moscow. URL: (in Russ).
  29. Stupak VS, Levkova EA. Theoretical and practical aspects of the treatment of patients at risk in the epidemic of highly pathogenic influenza A/H1N1. Far Eastern Journal of Infectious Pathology. 2010;17(17):25—27. (in Russ).
  30. Wassertheil-Smoller S. Biostatistics and Epidemiology. New York: Springer-Verlag. 1995:185.
  31. Romanenko NA, Bessmeltsev SS, Chechetkin AV. Correction of the immune status of patients with human immunoglobulin for intravenous administration. Kazan medical journal. 2017;5:775—783. (in Russ).



Abstract - 327

PDF (Russian) - 160




Copyright (c) 2021 Levkova E.A., Sepiashvili R.I., Savin S.Z.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies